Select a medication above to begin.
Jascayd
nerandomilast
Adult Dosing .
Dosage forms: TAB: 9 mg, 18 mg
idiopathic pulmonary fibrosis
- [18 mg PO bid]
- Max: 36 mg/day; Info: may decr. dose to 9 mg PO bid if tolerability concern; do not cut/crush/chew tab, but may disperse tab in water
progressive pulmonary fibrosis
- [18 mg PO bid]
- Max: 36 mg/day; Info: may decr. dose to 9 mg PO bid if tolerability concern; do not cut/crush/chew tab, but may disperse tab in water
renal dosing
- [see below]
- eGFR >15: no adjustment; eGFR <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
Drug Interactions .
Overview
nerandomilast
PDE4 inhibitor
- CYP3A4 substrate
Avoid/Use Alternative
- apalutamide
- bosentan
- butalbital
- carbamazepine
- cenobamate
- dabrafenib
- efavirenz
- encorafenib
- enzalutamide
- etravirine
- fexinidazole
- fosphenytoin
- ivosidenib
- lopinavir/ritonavir
- lorlatinib
- lumacaftor/ivacaftor
- mavacamten
- mitapivat
- mitotane
- modafinil
- nafcillin
- pacritinib
- pentobarbital
- pexidartinib
- phenobarbital
- phenytoin
- primidone
- repotrectinib
- rifabutin
- rifampin
- rifapentine
- sotorasib
- St. John's wort
Monitor/Modify Tx
- adagrasib
- atazanavir
- ceritinib
- chloramphenicol
- clarithromycin
- cobicistat
- idelalisib
- itraconazole
- ketoconazole
- levoketoconazole
- lonafarnib
- mifepristone
- nefazodone
- nelfinavir
- posaconazole
- ribociclib
- ritonavir
- tipranavir
- tucatinib
- voriconazole
Caution Advised
- pirfenidone
Adverse Reactions .
Serious Reactions
- malignancy
- atrial fibrillation
Common Reactions
- diarrhea
- URI
- depression
- weight decr.
- nausea
- appetite decr.
- fatigue
- headache
- vomiting
- back pain
- dizziness
- asthenia
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; no human data available; risk of fetal death based on animal data at 5x MRHD
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: for nerandomilast: liver; CYP450: 3A4 substrate; UGT: substrate (enzymes not defined)
Excretion: for nerandomilast: feces 58% (14% unchanged), urine 36% (13% unchanged); Half-life: 17h
Subclass: Interstitial Lung Disease ; Phosphodiesterase 4 (PDE4) Inhibitors, Pulmonary
Mechanism of Action
for nerandomilast: inhibits phosphodiesterase type 4B (PDE4B), leading to increased intracellular cAMP levels and reduced expression of pro-fibrotic growth factors and inflammatory cytokines
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.